Posted in M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers April 15, 2026 BioPharma Dive Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. M&A / DealsImmunology & InflammationRead full story